NorAD is a clinical trial funded by the UK National Institute of Health Research. In this
trial the investigators will assess whether a long-acting preparation of guanfacine, a drug
used to treat Attention Deficit Hyperactivity Disorder in children, can improve thinking
(particularly attention) in Alzheimer's Disease when it is added to the standard
NICE-approved drugs that are normally used in this condition.
This is a randomized clinical trial designed to evaluate the efficacy of extended-release
guanfacine as an add-on therapy in AD, and whether it improves cognition compared to standard
cholinergic therapy alone.